Effect of glycopyrronium bromide as preanesthetic medication on intraoperative pulmonary ventilation and postoperative pulmonary complications

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094363

Enrollment

Unknown

Registered

2024-12-20

Start date

2023-06-07

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intraoperative pulmonary ventilation and postoperative pulmonary complications

Interventions

Control group:Intravenous injection of equal volume of normal saline 10 minutes before anesthesia induction

Test group:intravenous injection glycopyrrolate 6ug/kg 10 minutes before anesthesia induction

Eligibility

Sex/Gender

All

Age

19 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients at high risk of developing PPCs in the respiratory risk score of ARISCAT Catalan surgical patients, 2.ASA physical status I-III, 3.Aged>18 years, 4.Patients without severe systemic diseases before surgery.

Exclusion criteria

Exclusion criteria: 1.BMI>35kg/m^2 or <18kg/m^2, 2. Patients who have undergone chest surgery, 3. Patients with thoracic deformities, 4. Patients with severe systemic diseases before surgery, 5. Glaucoma, urinary tract obstruction, intestinal obstruction, myasthenia gravis, allergies to glycopyrronium bromide.

Design outcomes

Primary

Measure	Time frame
pulmonary impedance values;The incidence of postoperative pulmonary complications;	—

Secondary

Measure	Time frame
oxygenation index ;Fiberoptic bronchoscopy examination of airway secretions and airway mucosal;	—

Countries

China

Contacts

Public ContactLi Jian

The Fourth Affiliated Hospital of Soochow University(Dushu Lake Hospital Affiliated to Soochow University)

Kentleesz@suda.edu.cn+86 137 7170 4822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026